

Disclosure Statement is submitted after the first Office Action on the merits, but before the issuance of a final action or a notice of allowance, Applicants hereby expressly authorize the Commissioner to charge the appropriate fee of \$240.00 (or other amount as required under 37 C.F.R. 1.17(p)) to Deposit Account No. 01-0025. Duplicate copies of this sheet are enclosed.

The following references are known to Applicants:

1. Kempf, et al., U.S. Patent No. 5,674,882, issued October 7, 1997. This reference is the parent of the present divisional patent application.
2. Dybas, et al., U.S. Patent No. 4,172,094, issued October, 1979.
3. Regel, et al., U.S. Patent No. 4,618,619, issued October 1986.
4. Kettner, et al., U.S. Patent No. 4,644,055, issued February, 1987.
5. Kettner, et al., U.S. Patent No. 4,652,552, issued March, 1987.

Copies of these references are enclosed. Applicants respectfully request that these references be made of record.

#### **Section 112 Objection/Rejection**

The Examiner has objected to the specification and rejected Claims 29, 34, 36 and 43-45 under 35 U.S.C. 112 as failing to provide an enabling disclosure and be supported by an enabling disclosure. The Examiner states that the specification fails to provide information that would allow the skilled artisan to practice the instant invention without undue experimentation. Applicants assert that the claimed invention is fully enabled by the present specification. The specification clearly teaches how one determines a compound to be an inhibitor of HIV protease and numerous examples of such compounds are provided. No undue experimentation would be required on the part of one of ordinary skill in the art to determine whether or not a given compound is an inhibitor of HIV protease. Furthermore, the Examiner has previously allowed claims of similar scope in U.S. Patent No. 5,674,882, the parent of the present divisional application.

Therefore, Applicants respectfully request that the Examiner reconsider and withdraw the Section 112 objection and rejection.

**Section 101 Rejection**

The Examiner has rejected Claims 48-52 under 35 U.S.C. 101 as being non-statutory. Without acquiescing to the rejection, but in an effort to advance the prosecution of this application, Applicants have cancelled Claims 48-52 by amendment herein.


**Action Requested**

In view of the above, reconsideration and allowance of Claims 29-47 is respectfully requested.

Applicants also respectfully request that the Examiner return to Applicants initialled copies of the Form PTO1449 dated March 20, 1997 and the new Form PTO1449 dated March 16, 1998.

Respectfully submitted,

D. Kempf, et al.



Dr. Steven R. Crowley  
Registration No. 31,604  
Agent for Applicant

Abbott Laboratories  
D-377/AP6D-2  
100 Abbott Park Road  
Abbott Park, IL. 60064-3500  
Telephone: (847) 937-9516

SRC/mac